DRUG COMPANIES CASHING IN ON COVID

For over a year now, since COVID-19 was first reported spreading across Europe and the U.S., the Trends Journal has pointed out how political leaders, with the mainstream press as cheerleaders, frequently refer to the challenge of COVID-19 as a “War.”
(See our 13 April article, “MEDIA: GET JABBED, END THE COVID WAR,” our 24 March 2020 article, “CORONAVIRUS: POLITICAL LEADERS ON THE WARPATH,” and our 21 July 2020 article, “COVID WAR: FEAR SELLS COVID WAR: FEAR SELLS.”)
And, now, as with all wars in which the suppliers of weapons reap the financial rewards, the “vaccine-industrial complex” is reaping tremendous financial rewards. 
Last Wednesday, Microsoft News ran the headline:

Pfizer sees COVID-19 as ‘durable’ revenue stream as profits rise

Indeed, as with the military/industrial/intelligence complex, “durable” equates to making a lot of money selling products to the government repeatedly over years.
The Microsoft article notes that Pfizer, maker of one of the popular COVID vaccines on the market, “sharply increased its 2021 profit projections on Tuesday, citing much higher COVID-19 vaccine sales,” and that with BioNTech, its German partner, they now estimate “2021 revenues of $26 billion from the vaccine, up from the $15 billion projected in February.”
More Drug Money
Moderna, the smaller Cambridge, MA company which also launched a COVID vaccine, generated revenues of $1.73 billion in the first quarter, registering its first-ever profitable quarter.
As the Wall Street Journal noted, “Moderna also boosted its full-year forecast of COVID-19 vaccine sales to $19.2 billion based on advanced purchase agreements… the forecast points to a booming market for COVID-19 vaccines.”
Profiteering Off Young Teens 
Pfizer has said it is close to winning U.S. approval for those aged 12 to 15 to receive its vaccine and is holding talks with “basically all governments of the world” about providing booster shots through 2024.
And, on cue, yesterday, the FDA approved Pfizer and BioNTech’s request to allow their COVID jab to be given to kids aged 12 to 15 on an emergency use basis, allowing states to get middle school students vaccinated before the fall.
TRENDPOST: As previously cited in the Trends Journal, teenagers are not at any significant risk from the coronavirus unless they are obese or significantly overweight.
(See our 4 May article,COVID-19 & OBESITY: THE ELEPHANT IS STILL IN THE ROOM,” our 17 November 2020 article, “MORE EVIDENCE KIDS DON’T SPREAD COVID TO ADULTS,” and our 3 November 2020 article, “CRUCIAL COVID DATA IGNORED BY PRESSTITUTES.”
There are reports now coming out that as a result of the lockdowns and new ABnormal regulations imposed on citizens, once normal-weight children have become overweight and/or obese and are suffering from high blood pressure, high cholesterol, fatty liver disease, and Type 2 diabetes. 
As reported in the Wall Street Journal, a May study in the journal Pediatrics found that the percentage of children ages 2 to 17 who are obese increased to 15.4 percent in June to December 2020 compared with 13.7 percent in the year-earlier period. 
The article noted that children categorized as overweight increased to about 16 percent from about 14 percent, and the biggest increase in obesity was in children ages 5 to 9 – their obesity rate increased to 16.8 percent from 14.2 percent. 
TREND FORECAST: There will be growing market opportunities to provide whole health healing weight loss programs that differ from mainstream regimes for both young and old. Beyond food, exercise, meditation, etc., the programs will include lifting the individuals’ looks and style to accentuate their personalities. 
TRENDPOST: As we reported, but is barely mentioned in the U.S. media, was the statement in early April by Dr. Özlem Türeci, co-founder and Chief Medical Officer of BioNTech (which developed a COVID vaccine with Pfizer), who told CNBC that people will need a third shot of the two-shot vaccine. She also indicated that similar to the seasonal flu, people will need to get their COVID jab annually. 
Using CNBC as their shill network, as we reported in the 20 April Trends Journal, Pfizer CEO Albert Bourla told the network people will “likely” need a third dose as well. In our article, “PFIZER CEO: THIRD TIME IS A CHARM,” we wrote:
Go back to when so-called health experts, politicians, and the media began selling the COVID Jab. The line was that after two jabs, you’d live happily ever after, COVID-free for the rest of your life.
In a blink of a Drug Lord’s eye, that line changed.
Last Friday, this was the CNBC headline: 

Pfizer CEO Albert Bourla said people will ‘likely’ need a third dose of a COVID-19 vaccine within 12 months of getting fully vaccinated.

Pfizer had put out a press release stating its clinical trial showed the vaccine to be effective six months after a second shot. But the CNBC report clarifies that “more data is still needed to determine whether protections last after six months.”

Comments are closed.

Skip to content